Microba Life Sciences (MAP) investor relations material

Executive summary

• FY26 core testing revenue rose 92% year-on-year, with core testing volume up 78% to 22,418 tests, driven by strong growth in Australia and the UK.

• Q4 FY26 core testing volume up 54% year-on-year, with an annualised run rate exceeding 25,000 tests across Australia and the UK.

• Strategic transition completed to focus on scalable core testing and higher-margin own-brand supplements, phasing out legacy products.

• Continuing product revenue increased 53% YoY, while discontinued product revenue declined 72% YoY, highlighting a focus on high-performing offerings.

• New GI Navigator diagnostic product set for launch in September 2026, with early access sales already achieved.

Financial highlights

• FY26 core testing revenue reached $9.0M, up 92% YoY, driven by increased test volumes.

• Q4 FY26 total revenue was $4.07m, up 21% QoQ; FY26 total revenue $14.78m, down 6% YoY due to legacy product phase-out.

• Invivo Supplements revenue in Q4 was $0.75m, up 11% quarter-on-quarter and year-on-year; PHGG Prebiotic Fiber unit sales more than doubled to 43,000 units, up 114% YoY.

• Cash and equivalents at 30 June 2026 were $7.95m.

• Q4 FY26 cash receipts were $3.95m, flat QoQ and YoY; net cash used in operating activities for Q4 was $3.43m, down 38% YoY.

Outlook and guidance

• Targeting full group cash flow breakeven on a run rate basis in 2027 by leveraging completed infrastructure and streamlining costs.

• Continued focus on growing test sales, clinical adoption, and launching GI Navigator in September 2026.

• Therapeutics partnering campaign to commence July 2026, leveraging recent positive sector clinical trial results.